pproximately 47% of the National Institutes of Health (NIH) budget, which oversees Americans' health, funds experiments on animals. We need a better way—and our scientists have devised it.

Clinical development of Hu5c8, a monoclonal antibody against CD40L intended for treatment of autoimmune disorders, was terminated due to unexpected thrombotic complications. These life-threatening si...

Thrombotic Antiphospholipid Syndrome (TAPS) is an autoimmune disorder associated with a high risk of recurrent thromboembolic events. Despite advances in anticoagulation, predicting recurrence remains...

BACKGROUND: Venous thromboembolism (VTE) is a major cause of morbidity and mortality worldwide. Current risk assessment tools, such as the Caprini and Padua scores and Wells criteria, have limitations...

A subset of coronavirus disease 2019 (COVID-19) patients develops severe symptoms, characterized by acute lung injury, endothelial dysfunction and microthrombosis. Viral infection and immune cell acti...

Read the latest article version by Jacob Ranjbar, Jonathan M. Gibbins, Jordan Roe, Paul Roach, Ying Yang, Alan G.S. Harper, at F1000Research.

There is a need for scalable automated lab-on-chip systems incorporating precise hemodynamic control that can be applied to high-content screening of new more efficacious antiplatelet therapies. This paper reports on the development and characterization of a novel active micropump-mixer microfluidic to address this need. Using a novel reciprocating elastomeric micropump design, we take advantage of the flexible structural and actuation properties of this framework to manage the hemodynamics for on-chip platelet thrombosis assay on type 1 fibrillar collagen, using whole blood. By characterizing and harnessing the complex three-dimensional hemodynamics of the micropump operation in conjunction with a microvalve controlled reagent injection system we demonstrate that this prototype can act as a real-time assay of antiplatelet drug pharmacokinetics. In a proof-of-concept preclinical application, we utilize this system to investigate the way in which rapid dosing of human whole blood with isoform selective inhibitors of phosphatidylinositol 3-kinase dose dependently modulate platelet thrombus dynamics. This modular system exhibits utility as an automated multiplexable assay system with applications to high-content chemical library screening of new antiplatelet therapies.

Deep vein thrombosis is a life-threatening disease that takes millions of people's lives worldwide. Given both technical and ethical issues of using animals ...

Animal models have long supported biomedical research, particularly in the development of drugs and preclinical testing. Yet, persistent discrepancies betwee...

The use of non-animal, new approach methodologies (NAMs) is increasing but there has been no associated decrease in animal use. Reasons may include th…